evidencegaps
Primary study · included by 1 review

Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.

Satapathy 2023 · Satapathy Swayamjeet, Tupalli Avinash, Chandekar Kunal Ramesh, et al. · Clinical endocrinology · 2023

Included by

Reassessing Radioactive Iodine Use After Thyroidectomy in Low-Risk Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis.
Non-Cochrane · intervention · 2026 · cited as Satapathy 2023 · Table 1; Fig. 3-8
Outcome this study informsPooled effectEvidenceCertainty
Recurrence
Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone)
OR 0.66 [0.41, 1.08]7 studies · 4101 participantsGRADE not reported
5-year recurrence-free survival
Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone) · 5 years
OR 4.70 [1.39, 15.97]3 studies · 2493 participantsGRADE not reported
5-year recurrence-free survival
Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone) · 5 years
OR 2.47 [0.63, 9.62]4 studies · 2997 participantsGRADE not reported

1 including review in total.